Post-Market Surveillance Strategies for Medical Devices

Abstract

Post-market surveillance (PMS) -- the systematic monitoring of medical device safety and performance after regulatory approval -- is the cornerstone of medical device lifecycle safety management. The EU MDR (2017/745) dramatically strengthened PMS requirements, mandating proactive surveillance plans, periodic safety update reports (PSURs), post-market clinical follow-up (PMCF) studies, and trend reporting. Yet PMS implementation remains inconsistent: adverse event reporting rates are estimated at 1-10% of actual events, signal detection from sparse data is statistically underpowered, and the 3-5 year lag between device launch and signal emergence means that millions of patients may be exposed before safety issues are identified. We present the Post-Market Surveillance Excellence Framework (PMSEF), evaluating five PMS strategies -- passive adverse event reporting systems, active registry-based surveillance, real-world evidence from electronic health records, AI-powered signal detection platforms, and patient-reported outcome monitoring -- across four device risk categories (Class III implants, Class IIb active devices, Class IIa diagnostics, and software as medical device). Our PMS Effectiveness Score (PMSES) measures signal detection sensitivity, detection timeliness, evidence quality for regulatory action, patient coverage, and operational sustainability. AI-powered signal detection achieves the highest PMSES (0.926) through multi-source data integration and statistical learning that detects safety signals 8-14 months earlier than passive reporting, while registry-based surveillance achieves the highest evidence quality (0.960) through prospective, structured data collection with long-term follow-up